Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
Noa Biran, MD, discusses how the phase III BOSTON trial evaluates selinexor + bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed/refractory myeloma.
Video Player is loading.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
Now Viewing
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
Recent Videos
MonumenTAL-1: Implications of Talquetamab, Prior TCR, and Sequencing for R/R MM
Insights From MonumenTAL-1: Impressions of Updated Efficacy Outcomes
Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
Current Treatment Approaches in HER2+ Metastatic Breast Cancer
Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
CEPHEUS Trial: Design/Baseline Characteristics
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Advances in ADC Therapy for Ovarian Cancer
ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
Looking Ahead: What’s on the Horizon in Advanced Melanoma
